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There is increasing evidence for the involvement of mitochondrial dysfunction and oxidative stress in the
pathogenesis of many of the major neurodegenerative and neuroinﬂammatory diseases, suggesting that
mitochondrial and antioxidant pathways may represent potential novel therapeutic targets. Recent years
have seen a rapidly growing interest in the use of therapeutic strategies that can limit the defects in, or
even to restore, mitochondrial function while reducing free radical generation. The peroxisome pro-
liferation-activated receptor gamma (PPARγ), a ligand-activated transcription factor, has a wide spectrum
of biological functions, regulating mitochondrial function, mitochondrial turnover, energy metabolism,
antioxidant defence and redox balance, immune responses and fatty acid oxidation. In this review, we
explore the evidence for potential beneﬁcial effects of PPARγ agonists in a number of neurological dis-
orders, including Parkinson’s disease, Alzheimer’s disease, Amyotrophic lateral sclerosis and Hunting-
ton’s disease, ischaemia, autoimmune encephalomyelitis and neuropathic pain. We discuss the me-
chanisms underlying those beneﬁcial effects in particular in relation to mitochondrial function, anti-
oxidant defence, cell death and inﬂammation, and suggest that the PPARγ agonists show signiﬁcant
promise as therapeutic agents in otherwise intractable neurological disease.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The peroxisome proliferator-activated receptor (PPAR) was
originally cloned from liver peroxisomes, which are organelles that
participate in the metabolism of fatty acids [77]. PPARs are ligand-r Inc. This is an open access article
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).inducible transcription factors that belong to the hormone nuclear
receptor superfamily. PPAR activation is involved in cellular dif-
ferentiation and proliferation, angiogenesis, vascular protection
and regulation of blood pressure. PPAR activation is also anti-
apoptotic, anti-oxidant, anti-inﬂammatory, and limits cancer me-
tastasis [13,19,24,41,44,129,160]. In addition to these effects, PPARs
also play key roles in the regulation of metabolism, regulating
insulin sensitivity, mitochondrial biogenesis, and glucose and lipid
homoeostasis [15,23,168]. As lipid sensors, PPARs modulate me-
tabolism in response to dietary lipid intake and direct lipid storage
and metabolism [106].
Three members of the PPAR family have been cloned, encoded
by three distinct genes located on human chromosomes 22, 6 and
3: PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3) re-
spectively [48]. While the three PPAR isoforms share a high degree
of structural similarity, they have distinct physiological roles, li-
gand speciﬁcity and tissue distribution. Mutations of each of the
PPAR isoforms has been associated with hereditary disease. Some
mutations of the PPARs lead to a loss of function, resulting in fa-
milial partial lipodystrophy, acanthosis nigricans or insulin re-
sistance [10,26,173]. Dysfunction of each of the three PPAR iso-
forms has been speciﬁcally implicated in dysfunction in the central
nervous system (CNS), suggesting key roles for these pathways in
maintaining the integrity of the nervous system.under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Natural and synthetic ligands, physiological role, and tissue expression of PPARγ.
Natural ligands Refs. Synthetic ligands Refs. Tissue expression Refs. Physiological role Refs.
Unsaturated Fatty Acids [44] Pioglitazone [88] High-Adipose tissue (white and brown) [1,155] Glucose homoeostasis [42,133]
Prostaglandin A1 [8] Rosiglitazone [96] Low-Intestines, Liver, Retina [16] Lipid storage [155]
15-deoxy-Δ12,14-PGJ2 [180] Troglitazone [96] Low-Heart [16] Differentiation and maturation
of adipocytes
[155]
Nitroalkenes [140] Ciglitazone [122] Low-Muscle [162] Fatty acid oxidation [14,15]
Oxidized phospholipids [39] Glitazars [2] Low-Brain (oligodendrocytes, neurons,
astrocytes, microglia)
[61,109]
PPARγ modulators [177]
Non-steroidal anti-in-
ﬂammatory drugs
[95]
Fig. 1. Chemical structures of TZD, 15-deoxy-Δ12,14-PGJ2, Rosiglitazone, Pioglita-
zone, Troglitazone and the antagonist GW9662.
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wide variety of tissues [20,124]. PPARα was cloned as the mole-
cular target of ﬁbrates, cholesterol-lowering compounds that in-
crease hepatic fatty acid oxidation [77]. The expression pattern of
PPARα is restricted to tissues with a high capacity for fatty acid
oxidation, such as heart, liver, brown adipose tissue (BAT), and
oxidative muscle [16]. The function of PPARα seems to be more
restricted to fatty acid uptake, beta-oxidation, and ketogenesis. In
contrast, PPARδ is ubiquitously expressed, with higher levels in the
digestive tract, heart, and BAT [52]. PPARδ plays a role in con-
trolling oxidative metabolism and fuel preference, mainly in re-
lation to fatty acid oxidation, mitochondrial OXPHOS, and glucose
utilization [92,98].
PPARγ is probably the most intensively studied of the three
isoforms [160]. Knockout of PPARγ is embryonically lethal [7,143].
PPARγ activation is associated with increased carbohydrate and
lipid metabolism, reduction of plasma glucose concentration and
stimulation of adipocyte differentiation [53]. PPARγ agonists are
currently in clinical use for the management of type 2 diabetes
[11,168]. The physiological roles of PPARγ are highlighted in
Table 1.
All PPARs can be activated by polyunsaturated fatty acids, but
with different afﬁnities [11,44,87]. Speciﬁc PPARγ ligands are di-
vided into two major groups: [26,34,163]: (i) Endogenous or nat-
ural agonists and (ii) synthetic agonists. The endogenous agonists
are divided into four subgroups: (i.1) The eicosanoids pros-
taglandin-A1 [8] and the cyclopentenone prostaglandin 15-deoxy-
Δ12,14-Prostaglandin J2 (15D-PGJ2), which is the most naturally
occurring and is commonly used as a potent ligand for PPARγ
[180]; (i.2) unsaturated fatty acids such as Linoleic acid and Doc-
osahexaenoic acid; (i.3) Nitroalkenes such as Nitrated oleic acid
and Linoleic acid [140]; and (i.4). oxidized phospholipids such as
hexadecyl azelaoyl phosphatidylcholine and Lysophosphatidic acid
[39]. Non-steroidal anti-inﬂammatory drugs, as ﬂufenamic acid,
ibuprofen, fenoprofen, and indomethacin A, are also PPARγ ligands
[11,12,95,178].(ii) The synthetic agonists are divided into ﬁve subgroups: (ii.1)
The thiazolidinedione (TZD) family, which include Rosiglitazone,
Pioglitazone and Troglitazone [88,96]; (ii.2) the non-TZD agonists,
such as Ciglitazone [122], Netoglitazone and Rivoglitazone; (ii.3)
the dual α/γ agonists [2] also called glitazars (Include: Aleglitazar,
Muraglitazar, Tesaglitazar and Saroglitazar); (ii.4) pan α/δ/γ ago-
nists like bezaﬁbrate; (ii.5) The selective PPARγ modulators
(SPPARγM) such as metaglidasen/halofenate, PA-082, INT131 be-
sylate and the angiotensin receptor antagonists [177]. The natural
and synthetic ligands of PPARγ are listed in Table 1.
The TZDs were the ﬁrst ligand family discovered to bind and
activate PPARγ with therapeutic beneﬁt for diabetic patients [96].
However, the TZDs do have some adverse effects in man, including
increased risk of heart failure, weight gain, increased cardiac load,
peripheral oedema and haemodilution [136,170]. While no en-
dogenous antagonists for PPARγ have been reported, some syn-
thetic antagonists are available, including GW9662, Bisphenol A
Diglyceryl ether, LG100641, SR-202, and PD068235. The structure
of some PPARγ agonist and antagonist are shown in Fig. 1.2. Distribution of PPARγ
PPARγ is distributed in a number of tissues and cell types
[16,43,133], demonstrated by in situ hybridization and by im-
munohistochemistry both in adult rat and in rat embryonic de-
velopment [16,17]. In man, PPARγmRNA expression was abundant
in adipose tissue, while lower level expression was seen in skeletal
muscle [162]. PPARγ protein and mRNA were expressed at low
levels in the adult rodent CNS, including neurons, astrocytes, mi-
croglia and oligodendrocytes [12,16,38,61,109]. High levels of ex-
pression of PPARγ have been found in discrete areas of the CNS,
including the stellate cells of the cerebellar cortex, the olfactory
tubercle, the piriform cortex, in rhomboid, centromedial, and
parafascicular thalamic nuclei and in the reticular formation
[61,109]. PPARγ is highly expressed in dopaminergic cells in the
basal ganglia [38,109]. Other studies have demonstrated the pre-
sence of PPARγ protein by Western blot and im-
munohistochemistry in the midbrain [22,120].
In cortical neurons, PPARγ immunoreactivity appears mainly as
nuclear labelling, although cytoplasmic staining is sometimes de-
tectable [109]. PPARγ is present at lower levels in liver, skeletal
muscle and heart, but it is abundantly expressed in white adipose
tissue. PPARγ is expressed in brown adipose tissue of rodents and
in the CNS during foetal development [1,17,107]. The tissue ex-
pression of PPARγ is shown in Table 1.3. PPARγ, adipose tissue, obesity and type 2 diabetes
The highest levels of PPARγ are expressed in adipose tissue
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induce adipogenesis [155]. Adipose tissue can be divided into two
major depots, white adipose tissue (WAT) and brown adipose
tissue (BAT). In both WAT and BAT, PPARγ is a key regulator of
differentiation. PPARγ plays an important role in regulating lipid
metabolism in mature adipocytes. WAT stores excess energy as
triglycerides, which can be mobilized by lipolysis to generate free
fatty acids for use by other tissues, while BAT is the site of non-
shivering thermogenesis, through activation of the brown adipo-
cyte-speciﬁc protein, uncoupling protein 1 (UCP1). TZDs appear to
co-ordinately activate gene expression leading to an increase in
net lipid partitioning into adipocytes [157]. Target genes directly
regulated by PPARγ, include lipoprotein lipase [139], fatty-acid
transport protein [58], and oxidized LDL receptor 1 [31], favouring
adipocyte uptake of phosphoenolpyruvate carboxykinase
[156,158], glycerol kinase [68], the glycerol transporter aquaporin
7 [73] and the circulating fatty acids.
Adipose tissue has generally been considered an organ used for
storage and release of energy. Recent years have seen an explosive
increase in the incidence of obesity worldwide, driving a re-
surgence of interest into the biology of adipose tissue, and of the
adipocyte as regulators of body energy homoeostasis. PPARγ is a
master regulator in the formation of fat cells and their normal
function in the adult [134,135]. PPARγ is induced during adipocyte
differentiation, and forced expression of PPARγ in non-adipogenic
cells effectively drives their differentiation into mature adipocytes
[155,157]. Adipose tissue accounts for about 10% of insulin-sti-
mulated glucose disposal and has a key role in directing whole-
body glucose homoeostasis. The discovery that the insulin-sensi-
tizing TZDs are potent agonists for PPARγ [55,96], suggested that
apart from being a fatty acid sensor, PPARγ might serve an im-
portant role as a regulator of glucose metabolism. TZDs act by
inhibiting hepatic glucose output and increasing insulin action to
stimulate muscle glucose disposal in insulin-resistant animal
models and patients [157].
Adipose tissue is dysfunctional in obesity, leading to pro-
gressive insulin resistance and risk for the development of type
2 diabetes. Phosphorylation of PPARγ at serine 273 by cyclin-de-
pendent kinase 5 (Cdk5) stimulates diabetogenic gene expression
in adipose tissues [30]. Inhibition of this modiﬁcation is a key
therapeutic mechanism of the TZDs. Insulin signalling activates the
Akt/PI3K and Grb2/Ras/MEK/ERK kinase cascades. Recently it was
demonstrated that ERK directly phosphorylates serine 273 of
PPARγ and Cdk5 suppresses ERKs through direct action on a novel
site in MEK, the ERK kinase. The pharmacological inhibition of
MEK and ERK markedly improves insulin resistance in both obese
and wild type ob/ob mice, and reversed the effects of the Cdk5
ablation, indicating that the ERK/Cdk5 axis controls the diabeto-
genic actions of PPARγ [5].
3.1. PPARγ coactivators
The binding of PPARγ to speciﬁc DNA sequences requires het-
erodimerization with a second member of the nuclear receptor
family, the retinoic X receptor. Binding of agonist ligands to PPARγ
triggers a conformational change that attracts transcriptional
coactivators, which exist in multiprotein complexes and include
members of the steroid receptor coactivator (SRC) family
[103,104]. SRC1 was originally identiﬁed as a coactivator of the
steroid receptor superfamily [118]. SRC1 also interacts with PPARγ
via LXXLL motifs in a ligand dependent manner [46]. The effects of
SRC1 and SRC2 on metabolism are predominantly mediated by
PPARγ coactivator 1α (PGC1α). PGC1α is upregulated in SRC2-
depleted BAT. SRC1 and SRC2 control the energy balance between
BAT and WAT. In BAT, SRC1 promotes energy expenditure via fatty
acid oxidation [181]. SRC2 represses this process by activation ofPPARγ in WAT, producing an increase in triglyceride accumulation
in WAT and a decrease in free fatty acids.
PGC1α is the master regulator of mitochondrial biogenesis and
plays a central role in coordinating and driving energy metabo-
lism, fatty-acid oxidation, gluconeogenesis, glucose transport,
glycogenolysis, peroxisomal remodelling, and oxidative phos-
phorylation [125,126]. PGC1α also integrates and coordinates the
activity of multiple transcription factors, such as nuclear re-
spiratory factor 1 and 2 (NRF1–2), PPARα and mitochondrial
transcription factor A (TFAM), which are all involved in mi-
tochondrial biogenesis [47,127].
PGC1α was originally identiﬁed in a two-hybrid screen using
murine BAT cDNA and PPARγ as bait [127]. The interaction with
PPARγ is ligand-independent and mediated through the N-term-
inal domain and an LXXLL motif [97,127]. PGC1α also targets other
transcription factors involved in metabolism, including FOXO1,
SREBP, Foxa2 and Sox9 [85,126,171]. PGC1α works in concert with
the oestrogen-related receptors (ERRα, ERRβ, ERRγ) which are
members of the nuclear hormone receptor family which promote
mitochondrial biogenesis in response to hormonal signals [47]. As
well as promoting mitochondrial biogenesis, PGC1α also regulates
the expression of several enzymes involved in antioxidant defence,
detoxifying reactive oxygen species (ROS). These include super-
oxide dismutases 1 and 2 (SOD1–2), catalase and glutathione
peroxidase-1 [146].
Other nuclear receptor coactivators are the histone acetyl
transferases p300 and CREB-binding protein (CBP) [6,117]. Both
proteins interact with the ligand binding domain of PPARγ in a
ligand- and LXXLL-dependent manner, while at the same time
they interact with the transcriptional activation domain (AF-1) of
PPARγ [64]. p300 and CBP enhance the transcriptional activity of
both the AF-1 and AF-2 domains separately. CBP and p300 are also
involved in adipogenesis.
PRDM16 is a BAT-speciﬁc transcription factor also involved in
mitochondrial biogenesis [142]. It is a zinc ﬁnger protein which
was ﬁrst identiﬁed at a chromosomal breakpoint in myeloid leu-
kaemia [116]. Overexpression of PRDM16 in cultured white pre-
adipocytes resulted in activation of the brown adipose differ-
entiation programme, the upregulation of mitochondrial genes,
increase of mitochondrial biogenesis and uncoupled respiration
[142]. Therefore, PRDM16 binds to PPARγ in a ligand-independent
manner, works as a DNA binding transcription factor and enhances
the transcriptional activity of PPARγ. PPARγ activation is required
for the adipogenic function of PRDM16,.4. Actions of PPARγ in rescuing mitochondrial function
Growing evidence suggests the involvement of mitochondrial
dysfunction in the pathogenesis of many diseases, and especially
in a number of major neurodegenerative and neuroinﬂammatory
disorders. This dysfunction is associated with defects in mito-
phagy, in bioenergetics, in mitochondrial fusion/ﬁssion and mi-
tochondrial trafﬁcking, frequently also in combination with oxi-
dative stress. Therefore, pharmacological pathways that promise
to enhance mitochondrial function, reduce generation of reactive
oxygen species (ROS) or enhance antioxidant defence represent
important new therapeutic prospects for these diseases.
4.1. Beneﬁcial actions of PPARγ on mitochondrial function
TZDs have been shown in many model systems to upregulate
mitochondrial oxidative phosphorylation, mitochondrial biogen-
esis and antioxidant defence, serving together to protect cells from
various forms of injury. Thus, TZDs were shown to protect lym-
phocytes from apoptosis following growth factor withdrawal,
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The survival-enhancing effects were dependent on both the pre-
sence and activation of PPARγ [165]. During the development of
obesity, in white adipocytes from ob/ob mice, which were treated
with rosiglitazone showed mitochondrial remodelling, enhanced
oxygen consumption and increased energy expenditure in white
fat, suggesting that enhanced lipid utilization in this tissue may
affect whole-body energy homoeostasis and insulin sensitivity
[169]. In human adipocytes, both TZDs rosiglitazone and piogli-
tazone signiﬁcantly increased mitochondrial DNA (mtDNA) copy
number and expression of factors involved in mitochondrial bio-
genesis, including PGC1α and TFAM while also increasing the ex-
pression of genes in the fatty acid oxidation pathway, including
carnitine palmitoyltransferase-1, malonyl-CoA decarboxylase, in-
creased the expression of UCP-1 and medium-chain acyl-CoA de-
hydrogenase [14,15]. A similar response was described in differ-
entiated 3T3-L1 and C3H/10T1/2 adipocytes treated with rosigli-
tazone, which showed increased mitochondrial biogenesis, oxygen
consumption and increased mitochondrial citrate synthase activity
[132]. Additionally, pioglitazone stabilized MitoNEET, a protein
that regulates oxidative capacity in 3T3-L1 cell line, rat brain mi-
tochondria and COS-7 cells [33,119,167].
Protection by TZDs has particularly been explored in relation to
the CNS, using a variety of model systems. Treatment with TZDs
protected cortical astrocytes in culture against cell death induced
by glucose deprivation, increasing glucose utilization, lactate pro-
duction and mitochondrial membrane potential (ΔΨm), demon-
strating modiﬁcation of astrocyte metabolism and mitochondrial
function following PPARγ activation [42]. Pioglitazone and ro-
siglitazone prevented the death of differentiated SH-SY5Y cells (a
neuroblastoma derived cell line), following glucose deprivation by
promoting mitochondrial biogenesis, indicated by the up-regula-
tion of PGC1α, NRF1, TFAM, cytochrome c oxidase subunit CO-I
and CO-IV, and an increased mtDNA copy number, while there wasFig. 2. Activation of PPARγ increases mitochondrial biogenesis, oxygen consumption, Δ
like PGC1α, NRF1–2, TFAM. Also PPARγ agonists regulate apoptosis and reduce inﬂamma
involved in neuronal survival and protected against neuronal death in several neurodeg
capacity.no change in ΔΨm [108].
In the human neuron-like NT2 cell line, pioglitazone treatment
also increased mtDNA content and the expression of nuclear-en-
coded electron transport chain subunit proteins. Oxygen con-
sumption was increased as well as complex I and complex IV V
(max) activities. Pioglitazone treatment was also associated with
increased cytoplasmic, but reduced generation of mitochondrial,
peroxide [65]. The natural ligand 15D-PGJ2 and rosiglitazone, both
PPARγ ligands, increased glucose metabolism in rat cortical slices
and astrocytes, restored brain ATP levels and prevented the im-
pairment of glutamate uptake induced by repeated stress in rat
brain [60]. In a more recent study, the PPARγ agonist ciglitazone
protected the mitochondrial population of hippocampal neurons
to oxidative stress (exposure to hydrogen peroxide). Protection
was attributed to the modulation of mitochondrial fusion-ﬁssion
events, suggesting that a PPARγ based therapy could have bene-
ﬁcial effects mediated by simultaneous actions on several com-
plementary cellular pathways [182]. An schematic overview of
PPARγ mechanisms is shown in Fig. 2.
4.2. Anti-oxidant and anti-apoptotic properties of PPARγ
Besides the protective effects of PPARγ on mitochondrial
function, the protective effects of PPARγ activation have also been
attributed to their anti-oxidant and anti-apoptotic properties.
Thus, in hepatocytes, rosiglitazone enhanced the antioxidant de-
fence of the cells, increasing the rate of elimination of ROS while
increasing the expression of nuclear factor erythroid-derived
2-like 2 (Nrf2) and the antioxidant enzyme haem oxygenase-1
(HO-1) through the PPARγ-pathway [164].
Rosiglitazone was protective against neuronal damage by
acetaldehyde, which causes oxidative neuronal death, inducing the
generation of intracellular ROS and ultimately causing apoptotic
cell death. The protection by rosiglitazone was attributed to theΨm, antioxidant defences, regulates autophagy, and increases transcription factors,
tion. Thus, PPARγ agonists like TZDs regulate the expression of several target genes
enerative disorders, mainly improving mitochondrial function and increasing redox
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SOD and catalase and by regulating the expression of B-cell lym-
phoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax) [83]. In an-
other study, treatment with pioglitazone was neuroprotective in
rats treated with lipopolysaccharide (LPS), decreasing degenera-
tion of dopaminergic pathways, decreasing inﬂammation and re-
storing mitochondrial function while also attenuating oxidative
stress [74]. Rosiglitazone or PPARγ overexpression protected the
neuronal N2A cell line against oxygen-glucose deprivation by
maintaining ΔΨm and preventing apoptosis [172].
Rosiglitazone treatment also protected the neuroblastoma de-
rived cell line, SH-SY5Y cells, against cytotoxicity induced by
chlorpyrifos (an acetylcholinesterase inhibitor, widely used as
pesticide). The protection was apparently mediated again by at-
tenuation of oxidative stress and by anti-apoptotic effects, as well
as the inhibition of the inﬂammatory cascade via inactivation of
signalling by p38, nuclear factor-κB (NF-κB) and c-Jun N-terminal
kinase [94].
Finally, in a model of bronchial asthma, oral treatment with
rosiglitazone signiﬁcantly increased anti-oxidant activity in lung
tissue, associated with improved lung function, improved histo-
pathological features and a signiﬁcant decrease in the serum levels
of IL-5 and IgE [51].5. Mechanisms of protection mediated by PPARγ
Here, we will discuss the neuroprotective effects of PPARγ in
relation to ischaemia, spinal cord injury, chronic neuropathic pain
and experimental autoimmune encephalomyelitis (EAE), a model
of Multiple sclerosis. We will also explore the literature relating to
several neurodegenerative disorders including Amyotrophic lateral
sclerosis (ALS), Huntington's disease (HD), Alzheimer’s disease
(AD) and Parkinson's disease (PD), beyond their mechanisms on
the mitochondrial function or on oxidative stress and apoptosis.
5.1. PPARγ actions on CNS ischaemic injury
PPARγ agonists may help to promote recovery after stroke.
Endogenous neuronal PPARγmay be important in limiting damage
after cerebral ischaemia, as PPARγ deﬁciency (PPARγ knock-out
mice) was associated with increased brain damage and oxidative
stress, a reduced expression of glutathione S-transferase, UCP-1,
catalase and SOD1 after cerebral ischaemia [179]. In contrast, ac-
tivation of PPARγ by the TZDs troglitazone or pioglitazone reduced
inﬂammation and infarct volume and improved neurological
function following middle cerebral artery occlusion in rats [149].
Treatment with rosiglitazone also reduced the infarct volume in a
rat model of transient focal ischaemia [161]. Treatment with ro-
siglitazone signiﬁcantly decreased DNA fragmentation, attenuated
infarct volume, neurological deﬁcits and neutrophilia after embolic
focal cerebral ischaemia in rats [3]. Recently, 15D-PGJ2 a natural
PPARγ ligand decreased neuronal autophagy by decreasing the
expression of proteins LC3-II, Beclin 1, cathepsin-B, and LAMP1
after cerebral ischaemia reperfusion injury [174]. A single injection
of rosiglitazone immediately following global cerebral ischaemia
signiﬁcantly increased neuronal survival and functional recovery
while reducing the cerebral infarct volume and brain oedema
[144]. All these data suggest that intrinsic PPARγ may be im-
portant in limiting stroke mediated injury and that further acti-
vation by TZDs may improve outcome.
5.2. PPARγ actions on pain and spinal cord injury
Neuropathic pain can be a major problem after spinal cord
injury. Several studies suggest that TZDs can limit chronic severepain and aid recovery from spinal injury. One study demonstrated
that PPARγ is essential for coupling ibuprofen to RhoA inhibition
and the subsequent promotion of neurite growth in primary
neurons. Also in the same study, a similar mechanism accounted
for the activation of PPARγ by ibuprofen in neuron-like PC12 and
B104 cells, suggesting a molecular mechanism that could re-
present a novel therapeutic target in spinal cord injury [45]. Aju-
lemic acid, which directly interacts with PPARγ and has a potent
analgesic and anti-inﬂammatory activity, may also be a potential
candidate for drug development in the treatment of pain [4].
In animal models, rosiglitazone and pioglitazone, improved
motor function, prevented myelin loss and reduced long term pain
after spinal injury in adult rats [121]. In a mouse model of neu-
ropathic pain, the intrathecal administration of rosiglitazone or
the natural ligand 15D-PGJ2 reduced nerve injury-induced allo-
dynia and hyperalgesia [32]. Additionally, pioglitazone reduced
tactile allodynia and thermal hyperalgesia in mice subjected to
peripheral nerve injury through attenuation of proinﬂammatory
cytokine secretion [100]. Intracerebroventricular administration of
rosiglitazone or 15D-PGJ2 reduced peripheral inﬂammation in the
brain, reduced inﬂammatory pain, induced the expression of Fos in
the dorsal horn, and inhibited local oedema [110].
Treatment of animals subjected to spinal cord injury with ro-
siglitazone signiﬁcantly increased the proliferation of neuronal
precursor cells, accelerated locomotor recovery and reduced NF-
κB expression [105]. Local administration of rosiglitazone sig-
niﬁcantly reduced hypersensitivity to heat and mechanical stimuli,
and paw swelling and reduced the development of post-incisional
pain, possibly by regulating macrophage polarity at the inﬂamed
site [71]. Attenuation of the development of inﬂammatory pain by
rosiglitazone was attributed to the induction of haem oxygenase 1
(HO-1) in macrophages, and gene induction of endogenous opioid
proenkephalin [70]. In rats with neuropathic pain, oral or in-
traperitoneal administration of pioglitazone limited multiple be-
havioural signs of somatosensory hypersensitivity and sig-
niﬁcantly reduced touch stimulus-evoked phospho-extracellular
signal-related kinase (p-ERK) [111].
5.3. PPARγ actions on EAE
Experimental allergic encephalomyelitis is often used as a
model of demyelinating disease. The pathophysiology of the dis-
ease model is complex, but a signiﬁcant body of data suggests key
roles of mitochondrial dysfunction and oxidative and nitrosative
stress [56,57,166]. In two models of EAE (immunized with myelin
oligodendrocyte glycoprotein peptide and with myelin basic pro-
tein), treatment with pioglitazone delayed neurodegeneration by
decreasing lymphocyte inﬁltration, reduced demyelination, che-
mokine and cytokine expression and increased inhibitor of kappa
B expression in the brain [54].6. Mechanisms of protection by PPARγ in neurodegenerative
diseases
6.1. Impact of PPARγ in Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS, also known as motoneuron
disease, MND), is a neurodegenerative disease that causes pa-
ralysis and shortened lifespan due to the selective death of mo-
toneurons. Extensive data point to a major role for calcium
mediated mitochondrial toxicity and oxidative stress in ALS in-
cluding a major role for excitotoxicity, which is a prime example of
calcium dependent mitochondrial toxicity [36,37,78]. The effects
of the PPARγ agonist troglitazone have been explored in rat mo-
toneurons, which showed improved survival. However,
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septal or hippocampal neurons [115]. These results indicate spe-
ciﬁc neurotrophic activity of troglitazone for motoneurons through
the activation of phosphatidylinositol 3-kinase (PI3-kinase) and
supported the potential value of troglitazone for the treatment of
motoneuron diseases such as ALS.
Mutations of SOD1 underlie MND in a rare subgroup of patients
with familial disease. The speciﬁc mechanism of MND/ALS caused
by mutations of SOD1 remain unclear – they are not simply due to
loss of antioxidant function but seem to involve a toxic gain of
function [137,176]. Pioglitazone protected transgenic mice carrying
the ALS related SOD1-G93A mutation from motoneuron neuro-
degeneration, improving muscle strength and body weight and
delaying disease onset [141]. In SOD1-G93A transgenic mice,
treatment with pioglitazone extended survival, reduced gliosis and
also reduced iNOS, NF-κB, and 3-nitrotyrosine immunoreactivity
in the spinal cord, suggesting a signiﬁcant role against nitrosative
stress [86]. In another study of the same mouse model, pioglita-
zone also protected motoneurons against p38-mediated neuronal
death and NF-κB-mediated glial inﬂammation [145]. The accu-
mulation of critical concentrations of lipid peroxidation adducts
during the progression of ALS leads to the activation of PPARγ in
motoneurons of SOD1-G93A mice. This in turn triggers self-pro-
tective mechanisms that involve the up-regulation of lipid detox-
iﬁcation enzymes, including lipoprotein lipase and glutathione
S-transferase α-2 [9].
Recently, in a Drosophila model of ALS based on TAR DNA-
binding protein 43 (TDP-43) that recapitulates several aspects of
ALS pathophysiology, pioglitazone rescued TDP-43-dependent lo-
comotor dysfunction in motoneurons and glia but not in muscles
and also was neuroprotective when FUS, but not SOD1, is ex-
pressed in motoneurons [81].
Finally, a randomized, double blind, placebo-controlled trial of
pioglitazone in combination with riluzole in ALS patients, dis-
appointingly found that treatment with pioglitazone had no po-
sitive beneﬁt, with no increase in the survival of ALS patients
treated with riluzole [50].
6.2. Impact of PPARγ in Huntington's disease
Huntington's disease (HD) is an autosomal dominant pro-
gressive neurodegenerative disorder associated with progressive
extrapyramidal motor dysfunction. It is a genetic disease, caused
by mutations that cause CAG trinucleotide expansion in the exon-1
region of the huntingtin gene. Extensive data links huntingtin
mutations and CAG repeats to mitochondrial damage and oxida-
tive stress [66,69,138].
The protective effects of PPARγ agonists have been studied in
several different models of HD. In striatal cells in culture expres-
sing mutant huntingtin STHdh(Q111), rosiglitazone increased mi-
tochondrial biogenesis and protected against calcium dependent
(thapsigargin-induced) mitochondrial dysfunction [128]. Similarly,
in cultured rat primary cortical neurons expressing mutant hun-
tingtin STHdh(Q111), PPARγ activation by rosiglitazone sig-
niﬁcantly attenuated thapsigargin-induced cell death, concomitant
with reduced caspase activation, a delay in the loss of ΔΨm, and a
reduction of ROS generation [80]. In addition, a reduction in mi-
tochondrial mass associated with the expression of mutant hun-
tingtin in N2A cells, was rescued by rosiglitazone [29]. Rosiglita-
zone also signiﬁcantly increased survival in N2A cells expressing
mutant huntingtin, while also upregulating the expression of
PPARγ, PGC1α, NRF-1, TFAM and improving mitochondrial func-
tion in mutant cells. Rosiglitazone treatment also normalized en-
doplasmic reticulum stress sensors Bip, CHOP and ASK1 and sig-
niﬁcantly reduced mutant huntingtin aggregates that included
ubiquitin and heat shock factor 1 and increased the levels of thefunctional ubiquitin-proteasome system and heat shock protein
27/70 [28].
PPARγ activation by pioglitazone protected striatal cells from
mitochondrial dysfunction and oxidative stress in a 3 ni-
tropropionic acid (3-NP)-induced experimental model of HD (3-
NP, irreversibly inhibits succinate dehydrogenase and produces in
animals behavioural, biochemical and morphologic changes con-
sidered to be similar to those occurring in HD). The beneﬁcial ef-
fects on mitochondrial dysfunction were attributed to interference
with the NF-κB signalling pathway, which has been implicated in
the pathogenesis of HD [112].
In a mouse model R6/2 of HD, treatment with rosiglitazone
rescued progressive weight loss, motor deterioration, formation of
mutant huntingtin aggregates, and reduced the expression of two
neuroprotective proteins, the brain derived neurotrophic factor
(BDNF) and Bcl-2 [27]. Bezaﬁbrate, a pan-PPAR agonist, increased
mitochondrial biogenesis, increased the numbers of muscle mi-
tochondria, improved survival, improved the phenotype and re-
duced brain, muscle and BAT pathology in transgenic mouse R6/2
[82]. Treatment with rosiglitazone also reduced huntingtin ag-
gregates and normalized the expression of PGC1α, NRF1–2, and
TFAM in the cortex of a transgenic mouse R6/2 [29]. Moreover,
chronic administration of rosiglitazone to N171–82Q HD mice
signiﬁcantly improved motor function, attenuated hyperglycae-
mia, rescued BDNF deﬁciency in the cerebral cortex, prevented
loss of orexin-A-immunopositive neurons in the hypothalamus,
prevented PGC1α reduction and increased Sirt6 protein levels [79].
6.3. Potential beneﬁts of PPARγ activators in Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by a progressive cognitive decline, associated with
intracerebral aggregates of amyloid-β (Aβ) protein and the accu-
mulation of the hyperphosphorylated tau protein. Substantial data
point to oxidative stress and mitochondrial dysfunction as major
contributors to the pathophysiology, although there is signiﬁcant
controversy about the relative roles of potential underlying me-
chanisms [21,49].
Acute treatment of APPV717I transgenic mice model of AD with
pioglitazone or ibuprofen signiﬁcantly decreased the number of
activated microglia and astrocytes in the hippocampus and cortex.
Both drugs reduced the expression of the proinﬂammatory en-
zymes COX-2 and iNOS and reduced Aβ deposits in the hippo-
campus and cortex [72]. In APPV717I transgenic mice, pioglitazone
treatment signiﬁcantly attenuated astroglial activation, reduced
signs of oxidative stress and normalized the cerebral blood ﬂow
and glucose uptake responses to increased neuronal activity, but
failed to improve spatial memory [114]. In AD Apolipoprotein E
(ApoE) knockout mice, rosiglitazone increased mitochondrial
biogenesis as demonstrated by the induction of both oestrogen-
stimulated related receptor alpha (ESRRA) mRNA and mtDNA copy
number and improved glucose utilization [147]. Treatment with
rosiglitazone improved cognition in the Tg2576 mice, another
transgenic mouse model of AD which presents accumulation of
Aβ, neuronal loss, and cognitive decline [131]. In the Tg2576 mice,
rosiglitazone enhanced cognitive function and normalized dentate
granule cell presynaptic function, through regulation of pre-
synaptic vesicular proteins critical for glutamatergic neuro-
transmitter release, synaptic transmission, and short-term plasti-
city [113].
In another mouse model of AD, the APPswe/PS1Δe9 mice,
treatment with pioglitazone reduced brain levels of soluble and
insoluble Aβ levels which correlated with the loss of both diffuse
and dense-core plaques within the cortex [101]. In another study
using the same APPswe/PS1Δe9 mice, the novel selective PPARγ
modulator, DSP-8658 and pioglitazone, improved spatial memory
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subsequently resulted in a reduction of cortical and hippocampal
Aβ levels. The phagocytosis of Aβ was mediated through the up-
regulation of scavenger receptor CD36 [175]. Activation of Wnt
signalling by lithium and rosiglitazone reduced spatial memory
impairment and neurodegeneration in brains of APPswe/PS1Δe9
mice, and both drugs also prevented changes in presynaptic and
postsynaptic marker proteins [153].
In Cdk5 conditional knock-out mice, astrogliosis, microgliosis,
neuronal loss and behavioural deﬁcit were all improved by ro-
sitglitazone. Cdk5 plays an important role in neurogenesis and
there is some evidence that it participates in the pathogenesis of
AD [159].
PPARγ activation by troglitazone and rosiglitazone protected
rat hippocampal neurons in culture against toxicity through ex-
posure to synthetic Aβ1–40 peptide (5 μM), resulting in the mod-
ulation of Wnt signalling components, including the increase of
the cytoplasmic and nuclear β-catenin levels and the inhibition of
glycogen synthase kinase-3β (GSK-3β), suggesting that GSK-3β is
responsible for the tau hyperphosphorylation in AD [75]. Fur-
thermore, in cultured hippocampal neurons, rosiglitazone was
protective against mitochondrial damage, oxidative stress and
apoptosis induced by 5 μM of synthetic Aβ1–40 peptide, through a
mechanism involving elevated expression of Bcl-2. Also, PPARγ
overexpression prevented H2O2-induced ROS, stabilized mi-
tochondria, and decreased Aβ-induced toxicity [59].
In a clinical trial, patients with mild-to-moderate AD were
randomized to placebo or rosiglitazone treatment and the ex-
ploratory analyses suggested an improvement in cognitive and
functional measures in ApoE ε4 non-carriers, whereas no im-
provement and some decline was noted in the ApoE ε4 allele
carriers [130]. In a further randomized, double-blind, placebo-
controlled phase III study in mild-to-moderate AD, rosiglitazone
monotherapy failed to show any beneﬁt in cognition or in global
function in ApoE ε4 negative subjects [67].
In addition, in a randomized pilot clinical trial of the safety of
pioglitazone in non-diabetic patients with AD, pioglitazone was
generally well tolerated with an increase in peripheral oedema
(oedema is a commonly recognized effect of pioglitazone in clin-
ical use and this potential adverse treatment effect was antici-
pated) and there were no other serious or unanticipated adverse
events or clinical laboratory changes attributable to pioglitazone
over a long-term exposure [63]. Some clinical trials of different
PPARγ agonist for the treatment of neurodegenerative diseases are
shown in Table 2.
6.4. Impact of PPARγ in Parkinson's disease
Parkinson's disease (PD) is characterized by the progressiveTable 2
Some clinical trials of TZDs for the treatment of different neurodegenerative
diseases.
Agent Disease Outcome Refs.
RosiglitazoneþRiluzole ALS Had no positive beneﬁt [50]
Rosiglitazone AD No improvement in ApoE ε4 allele
carriers
[130]
Rosiglitazone AD No beneﬁt in cognition or in global
function in ApoE ε4 negative
subjects
[67]
Pioglitazone AD Well tolerated but an increase in
peripheral oedema
[63]
Glitazone PD A reduction in the incidence of PD in
patients with diabetes
[18]
Pioglitazone PD Is unlikely to modify progression in
early PD
[76]neurodegeneration of dopaminergic neurons of the substantia
nigra, causing a characteristic tremor, bradykinesia and a slower
deterioration of cognitive function. There are extensive data
pointing to impaired mitochondrial function and oxidative stress
as key mechanisms in the pathophysiology of the disease, most
notably pointing to complex I damage, impaired autophagy and
calcium dependent mitochondrial free radical generation for re-
views see: [49,99,148]. The neuroprotection of PPARγ activation
has been studied in a number of models of PD.
In human neuroblastoma cells in culture, rosiglitazone was
protective against mitochondrial dysfunction produced by the
complex I inhibitor 1-methyl-4-phenylpyridinium ion (MPPþ),
increasing ΔΨm, while also increasing the expression of SOD and
catalase, and the expression of Bcl-2 and Bax, thus promoting both
antioxidant defence and limiting apoptosis [84]. 15D-PGJ2 and
pioglitazone preserved mitochondrial function of oligodendrocyte
progenitors against the inhibitory activities of rotenone and cy-
tokine tumour necrosis factor α (TNFα), by maintaining ΔΨm,
reducing mitochondrial ROS production and by increasing the
expression of PGC1α, uncoupling protein 2 (UCP-2) and cyto-
chrome oxidase subunit COX1. TNFα decreased Ca2þ oscillations,
as well as the frequency of the oscillatory events and the TNFα
effects were prevented by pioglitazone, also pioglitazone pro-
tected the oligodendrocyte progenitor differentiation to immature
oligodendrocyte [40]. In differentiated neuroblastoma SH-SY5Y
cells associated with chronic partial inhibition of complex I with
rotenone and with loss of PINK1 function, as cellular models re-
lated to sporadic and familial PD respectively, rosiglitazone in-
creased mitochondrial biogenesis, increased oxygen consumption,
increased mitochondrial mass, ΔΨm, mtDNA copy number, de-
creased autophagy and suppressed free radical generation [35]. A
novel thiobarbituric-like compound MDG548, which acts as a
functional PPARγ agonist, was tested in vitro and in vivo models of
PD, MDG548 protected against H2O2 and MPPþ neurotoxicity in
PC12 cells and in the mice treated with MPTP, the MDG548 re-
duced reactive microglia and iNOS induction in the substantia
nigra [91].
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) admin-
istration is used in animals to model PD, as it causes selective
death of dopaminergic neurons. The oxidative stress produced by
this toxin was reduced by pioglitazone treatment as evidenced by
a reduction in the levels of malondialdehyde and increased glu-
tathione levels [89]. In response to MPTP plus probenecid, treat-
ment with rosiglitazone was effective in protection against partial
degeneration of the substantia nigra and the decline of striatal
dopamine. Also, the production of the pro-inﬂammatory cytokine
TNFα by microglia was inhibited by rosiglitazone [22]. In another
study, rhesus monkeys were subjected to an intracarotid injection
of MPTP and pioglitazone was also shown to be neuroprotective
when administered early. Behavioural recovery was associated
with preservation of dopaminergic markers and reduced inﬁltra-
tion by CD68-positive macrophages in the nigrostriatal area and
by a signiﬁcant improvement in a clinical rating score [152].
A novel non-TZD partial PPARγ agonist LSN862, was shown to
be neuroprotective in MPTP-induced neurodegeneration, which
was associated with the modulation of PPARγ and PGC1α ex-
pression, the downregulation of neuroinﬂammation and de-
creased oxidative stress [151]. The expression of PPARγ in the
dopaminergic neurons of the substantia nigra pars compacta and
putamen of hemiparkinsonian nonhuman primates was promi-
nent and the dopaminergic neurons were more likely to survive
against MPTP-induced damage after activation by pioglitazone
[150]. In the MPTP-probenecid mouse model, the PPARγ agonists
may act through an immunomodulatory action, since the anti-in-
ﬂammatory microglia were stimulated and inﬂammatory micro-
glia were inhibited in the substantia nigra compacta by
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motor function and neuronal loss in the acute MPTP mouse model,
but failed to protect in a rat model using 6-hydroxydopamine (6-
OHDA) as a dopaminergic selective toxin, thought to reﬂect the
severity of damage caused by 6-OHDA [90]. The activation of
PPARγ receptors by rosiglitazone in the 6-OHDA-lesioned rat,
signiﬁcantly increased GFAP expression in the striatum and atte-
nuated COX-2 and TNFα expression [93].
In 2013, pioglitazone entered in a multicenter placebo-con-
trolled phase II study, in early PD (NCT01280123) and depending
on the study results, a subsequent phase III trial could follow.
Recently, in a retrospective cohort study, the prescription of the
PPARγ agonist glitazone in patients with diabetes was associated
with a reduction in the incidence of PD, suggesting that PPARγ
pathways may be a successful drug target in PD [18].
6.5. Impact of PPARγ in Friedreich’s ataxia
The effect of PPARγ activation has also been studied in Frie-
dreich’s ataxia, an autosomal recessive disorder caused by muta-
tions of the protein frataxin. The disease phenotype includes a
progressive cardiomyopathy which leads eventually to heart fail-
ure. It was demonstrated that PPARγ agonist increased both
messenger RNA and protein levels of frataxin [102]. Pioglitazone,
which seems to have fewer side effects than rosiglitazone is on a
phase III clinical trial for its neuroprotective properties. The pro-
ject, titled "Effect of pioglitazone administered to patients with
Friedreich’s ataxia: proof of concept". However, the antecedents
and possible consequences should be taken into consideration
when PPARγ agonist drugs are considered as possible therapeutic
agents for FRDA patients [62].7. Conclusion
The modulation of molecular pathways that include mi-
tochondrial dysfunction, oxidative stress, process of autophagy,
inﬂammation and apoptosis, which are implicated in the patho-
physiology of many major diseases including neurodegenerative
disorders seem to present very valuable therapeutic targets. In a
similar vein, PPARγ agonists have been showed to have a wide
range of activities that positively inﬂuence the pathology of dis-
eases in several experimental models, and have the capacity to be
neuroprotective by regulating the expression of genes involved in
neuronal survival processes and therefore promote the health of
neurons. PPARγ agonists could be valuable potential therapeutic
targets for several diseases including neurodegenerative disorders,
since the results from patients and from in vivo and in vitro
models of neurodegenerative disorders underline the beneﬁcial
effects of PPARγ agonists for future clinical trials. However, further
studies are needed if we are to understand the potential of PPARγ
agonists for patient beneﬁt or the mechanisms by which PPARγ
exerts its protective actions.References
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